Q1 FY2027 revenue rises 27%, PAT jumps over 53%

Revenue growth above 20%Profit growth above 25%Results View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.9%Reaction day

₹392.05

prior close

₹411.10

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.1%+4.8% vs market

Specialty Chemicals peers, median of 94sector-0.2%+5.0% vs sector

On the reaction day the stock moved 4.8 pts more than Nifty Microcap 250 and 5.0 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.0

15m

+0.0

30m

+0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.9+0.1+4.8-0.2+5.0

Next day

+5.1+0.2+4.9-1.1+6.2

+2.4+0.6+1.8-0.9+3.2

+1.4-0.0+1.4-1.2+2.6

+0.2+0.5-0.3-1.3+1.5

+2.3+0.8+1.5-1.0+3.3

-3.0+0.6-3.6-0.9-2.1

15d

+11.7+1.3+10.4+0.6+11.1

+6.2-1.4+7.6-2.0+8.2

+2.0-0.6+2.6-0.9+2.9

—————

UpDownMarket · Nifty Microcap 250Sector · Specialty Chemicals peers, median of 94Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Titan Biotech's board approved unaudited standalone and consolidated results for Q1 FY2027. Standalone operating revenue rose 27.3% to Rs 5,916.66 lakh from Rs 4,649.64 lakh, while PAT climbed 53.5% to Rs 945.59 lakh from Rs 616.08 lakh. Consolidated PAT was Rs 1,085.68 lakh, up 58.2% year on year. The auditor found no material misstatement, and no exceptional items were reported.

Likely market impact

Strong revenue and profit growth may support the stock; the results are unaudited, and cost growth needs monitoring.